Open main menu

Matthew Helmut Kulke is a Professor of Medicine at the Dana–Farber/Harvard Cancer Center. His work has shed light on the molecular characteristics of neuroendocrine tumors.[1][2][3] His research has led to the development of multiple new treatments for this condition.[4] He completed his MD at UCSF School of Medicine in 1992 and completed a masters degree in medical science at Harvard Medical School.[5] He has an h-index of 55.[6]


  1. ^ Chan, Jennifer A; Kulke, Matthew H (2011). "New Treatment Options for Patients with Advanced Neuroendocrine Tumors". Current Treatment Options in Oncology. 12 (2): 136–48. doi:10.1007/s11864-011-0148-2. PMID 21437592.
  2. ^ Kulke M H; et al. (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24 (22): 3555–3561. doi:10.1200/JCO.2006.05.6762. PMID 16877721.
  3. ^ Kulke MH, et al. "A Phase 2 Study to Evaluate the Efficacy of SU11248 in Patients with Unresectable Neuroendocrine Tumors". Presented at ASCO 2005. Available at:
  4. ^ "2015-2016 Recently Appointed Professors" (PDF). The Faculty of Medicine - Harvard University. Retrieved 16 January 2018.
  5. ^ "Matthew H. Kulke, MD". Dana–Farber/Harvard Cancer Center. Retrieved 16 January 2018.
  6. ^ "kulke m". Google Scholar. Retrieved 16 January 2018.